Eupraxia Pharmaceuticals Inc. Common Stock logo

Eupraxia Pharmaceuticals Inc. Common Stock(EPRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$8.15
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for EPRX

11/13/2026: EPRX (1-star) is currently NOT-A-BUY. Pass it for now.

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing extended-release alternatives using its proprietary DiffuSphere technology platform. The company's main strengths lie in its innovative drug delivery mechanism and advanced pipeline candidates such as EP-104IAR and EP-104GI targeting unmet medical needs. Its primary growth story centers on successful clinical trial readouts and potential commercial expansion into large therapeutic markets. Key risks include clinical trial uncertainties, lack of commercial revenue, and reliance on external financing. The stock best suits growth-oriented investors willing to accept high volatility, with key developments in clinical milestones and trial readouts to monitor closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers exposure to high-potential clinical-stage drug pipeline expansion.
Momentum investorStrong fit while signal remains positiveStock price movement is highly sensitive to clinical trial catalysts and positive market momentum.
Value investorWeak fitThe absence of current commercial revenue and earnings makes traditional valuation metrics inapplicable.
Dividend investorWeak fitThe company does not pay dividends and retains all capital for clinical development.
Low-risk investorWeak fitHigh clinical development risk and price volatility make it unsuitable for conservative risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks experience sharp price fluctuations based on trial results and news flow.
Valuation riskMedium / highValuation is heavily dependent on future clinical success and pipeline commercialization potential.
Competition risk (biotech clinical development)Medium / highIntense competition from other biopharma companies targeting similar indications could impact commercial potential.
Business qualityMediumProprietary technology platform provides strong scientific foundation, though commercial validation remains pending.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighThe company's success relies entirely on executing clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 548.24M USD
Price to earnings Ratio -
1Y Target Price 17.12
Price to earnings Ratio -
1Y Target Price 17.12
Volume (30-day avg) 698.9K shares
Beta 1.33
52 Weeks Range 5.63 - 9.32
Updated Date 11/15/2026
52 Weeks Range 5.63 - 9.32
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.02

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 10.16%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
EPRX receives a 3-star rating, supported by strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
EPRX has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and strong ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-51.3%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
EPRX's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is EPRX's strongest growth driver at +1.6% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while revenue growth (+0.0%, slightly negative) and earnings growth (-51.3%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 41.5% and approximately 84.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 12.06% supports management-shareholder alignment.

Top 5 Institutional Investors

Beutel, Goodman & Company Ltd. 5.40%
Affinity Asset Advisors, LLC 2.45%
Balyasny Asset Management LLC 2.01%
Vivo Capital, LLC 2.01%
Scotia Capital Inc 2.00%

Unit Economics (Per $1K Revenue)

★★★★★
EPRX generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.03%

Quantitative Style Profile

★★★★★
EPRX has a liquid profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Development & LicensingFuture commercialization rights, potential milestone payments, and collaborative research agreements stemming from the DiffuSphere drug delivery platform.The company currently operates pre-revenue and depends on future product approvals or partnerships to generate income.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 447.09M
Price to Sales(TTM) -
Enterprise Value 447.09M
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -2.85
Shares Outstanding 67.27M
Shares Floating 56.80M
Shares Outstanding 67.27M
Shares Floating 56.80M
Percent Insiders 12.06
Percent Institutions 41.53

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.